<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Immunology and Molecular Pathology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE09B175-4199-4BDE-B719-27BE271395B0"><gtr:id>AE09B175-4199-4BDE-B719-27BE271395B0</gtr:id><gtr:name>Private Address</gtr:name><gtr:address><gtr:line1>Private Address</gtr:line1><gtr:line4>Private Address</gtr:line4><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E6BCC648-330D-47CD-83EC-ADCFC97B5877"><gtr:id>E6BCC648-330D-47CD-83EC-ADCFC97B5877</gtr:id><gtr:firstName>Emma</gtr:firstName><gtr:otherNames>Kate</gtr:otherNames><gtr:surname>Nicholson</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0900397"><gtr:id>2DFDE879-BD9C-46C5-822A-CAAD61E18D9E</gtr:id><gtr:title>Enhancing the Efficacy of TCR Gene Therapy by Co-Transfer of CD3 Molecules</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0900397</gtr:grantReference><gtr:abstractText>Although the immune system can protect people against virus infection, its ability to protect against the growth of leukaemia cells is impaired. One reason for this impairment is that the immune
system often fails to recognise leukaemia cells. In this project, we will insert genes into immune cells in order to improve their ability to recognise leukaemia cells. We will optimise the gene transfer
strategy and test in an experimental model whether the gene modified immune cells can protect against the growth of leukaemia cells.</gtr:abstractText><gtr:technicalSummary>The adoptive transfer of TCR gene modified T cells provides new opportunities for the treatment of leukaemia, cancer and viral infections. Recently, the host laboratory has shown that co-transfer of TCR genes together with genes encoding the CD3 chains can enhance the function of TCRs in CD8+ T cells. In this project I will explore whether the co-transfer of CD3 genes can improve the function of MHC class I-restricted TCRs in CD4+ helper T cells. I will use murine tumour models to test whether TCR+CD3 gene transfer can enhance tumour protection by adoptively transferred CD4+ T cells without increasing on-target or off-target toxicity.
The following working hypotheses will be tested:
1) Co-transfer of TCR+CD3 enhances the functional activity of MHC-class I-restricted TCRs in CD4+ helper T cells.
2) Co-transfer of TCR+CD3 improves antigen-specific T cell function in vivo.
3) Adoptive transfer of TCR+CD3 modified T cells results in enhanced tumour protection in vivo.
4) Adoptive transfer of TCR+CD3 modified T cells does not result in on-target or off-target toxicity in vivo.
This project will provide me with extensive training in cellular and molecular immunology and in the use of animal models. The results will show whether TCR+CD3 gene transfer should be considered to improve TCR gene therapy in humans.</gtr:technicalSummary><gtr:fund><gtr:end>2012-10-05</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-10-06</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>265121</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>0340F383-79D5-41B0-BB8E-BADD510D6F10</gtr:id><gtr:title>CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54f9e3e773c769e589346684ebee8e7e"><gtr:id>54f9e3e773c769e589346684ebee8e7e</gtr:id><gtr:otherNames>Ghorashian S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5675de23b12d5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F1E99DA-5812-48D2-A793-F56D0E7D4FC4</gtr:id><gtr:title>T cell gene-engineering to enhance GVT and suppress GVHD.</gtr:title><gtr:parentPublicationTitle>Best practice &amp; research. Clinical haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54f9e3e773c769e589346684ebee8e7e"><gtr:id>54f9e3e773c769e589346684ebee8e7e</gtr:id><gtr:otherNames>Ghorashian S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1521-6926</gtr:issn><gtr:outcomeId>cPEgfDDqPsF</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900397</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>